Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Andersson

Showing results (51-60 of 95) with videos related to

Pageof 10
Sort By:
Clinical and Experimental Medicine|May 8, 2025
Transient increase in mitochondrial respiration in blood cells from breast cancer patients following chemo- and radiotherapyMarie-Louise Abrahamsen, Ida Bager Christensen, Linda Laizāne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2011
Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative GroupDorte Lisbet Nielsen, Karsten D Bjerre, Erik H Jakobsen, et al.
Acta Oncologica (Stockholm, Sweden)|February 9, 2011
Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1Per Edlund, Johan Ahlgren, Karsten Bjerre, et al.
Breast Cancer Research and Treatment|August 8, 2020
Patterns in detection of recurrence among patients treated for breast cancerLena Saltbæk, Trine Allerslev Horsboel, Birgitte Vrou Offersen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA studyMichael Andersson, Elisabeth Lidbrink, Karsten Bjerre, et al.
Acta Oncologica (Stockholm, Sweden)|August 1, 2017
The effects of individually tailored nurse navigation for patients with newly diagnosed breast cancer: a randomized pilot studyBirgitte Goldschmidt Mertz, Anne Katrine Dunn-Henriksen, Niels Kroman, et al.
Environmental Research|April 12, 2024
Aqueous mineral carbonation of three different industrial steel slags: Absorption capacities and product characterizationEmmanouela Leventaki, Eduarda Couto Queiroz, Shyam Krishnan Pisharody, et al.
Breast Cancer Research and Treatment|January 16, 2007
Leukemia following breast cancer: an international population-based study of 376,825 womenRegan A Howard, Ethel S Gilbert, Bingshu E Chen, et al.
Acta Oncologica (Stockholm, Sweden)|April 30, 2020
Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000-1Paula Poikonen-Saksela, Henrik Lindman, Asgerdur Sverrisdottir, et al.
Breast Cancer Research and Treatment|February 6, 2007
Risk of second non-hematological malignancies among 376,825 breast cancer survivorsLinda Morris Brown, Bingshu E Chen, Ruth M Pfeiffer, et al.
Pageof 10

Showing results (51-60 of 95) with videos related to

Sort By:
Pageof 10
Clinical and Experimental Medicine|May 8, 2025
Transient increase in mitochondrial respiration in blood cells from breast cancer patients following chemo- and radiotherapyMarie-Louise Abrahamsen, Ida Bager Christensen, Linda Laizāne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2011
Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative GroupDorte Lisbet Nielsen, Karsten D Bjerre, Erik H Jakobsen, et al.
Acta Oncologica (Stockholm, Sweden)|February 9, 2011
Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1Per Edlund, Johan Ahlgren, Karsten Bjerre, et al.
Breast Cancer Research and Treatment|August 8, 2020
Patterns in detection of recurrence among patients treated for breast cancerLena Saltbæk, Trine Allerslev Horsboel, Birgitte Vrou Offersen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA studyMichael Andersson, Elisabeth Lidbrink, Karsten Bjerre, et al.
Acta Oncologica (Stockholm, Sweden)|August 1, 2017
The effects of individually tailored nurse navigation for patients with newly diagnosed breast cancer: a randomized pilot studyBirgitte Goldschmidt Mertz, Anne Katrine Dunn-Henriksen, Niels Kroman, et al.
Environmental Research|April 12, 2024
Aqueous mineral carbonation of three different industrial steel slags: Absorption capacities and product characterizationEmmanouela Leventaki, Eduarda Couto Queiroz, Shyam Krishnan Pisharody, et al.
Breast Cancer Research and Treatment|January 16, 2007
Leukemia following breast cancer: an international population-based study of 376,825 womenRegan A Howard, Ethel S Gilbert, Bingshu E Chen, et al.
Acta Oncologica (Stockholm, Sweden)|April 30, 2020
Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000-1Paula Poikonen-Saksela, Henrik Lindman, Asgerdur Sverrisdottir, et al.
Breast Cancer Research and Treatment|February 6, 2007
Risk of second non-hematological malignancies among 376,825 breast cancer survivorsLinda Morris Brown, Bingshu E Chen, Ruth M Pfeiffer, et al.
Pageof 10